ARTICLE | Clinical News
CYT003-QbG10: Completed Phase IIa enrollment
February 15, 2010 8:00 AM UTC
Cytos completed enrollment of 60 patients in a double-blind, placebo-controlled, German Phase IIa trial evaluating 7 injections of 900 µg subcutaneous CYT003-QbG10 given over 10 weeks. ...